Reading VTR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VTR free→Reading VTR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VTR free→NYSEReal EstateReit - Healthcare FacilitiesSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral. Earnings quality is robust, cash backs up profits. Management's recent track record has been steady. Risk is moderate, and the sector backdrop is a headwind. Peer multiples imply a price about 48% below where it trades (it looks expensive on this basis); the read is expensive, growth-justified, as it is rich on today's multiple but looks cheaper over three years with expected earnings growth. If VTR cuts guidance on the next call, that could be a meaningful negative. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 7 valuation methods, at three horizons. Current price $83.88. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $83 VTR trades at 7× p/s, below its 8× p/s peer median. Our $53 fair value sits above the price; low confidence. Analysts: $93–$110. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 57% near-term growth, well above our forecast of about 22%. This describes what's priced in, not a forecast of the move.
Flags: expensive valuation, a turbulent sector regime (Heating).
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Real Estate names rated neutral grew net income 53% of the time over the next year (vs 57% for the rest of the cohort, n=1968).
Over the trailing year it converted 6.32x of net income into operating cash flow. Historically, Real Estate names rated robust grew net income 59% of the time over the next year (vs 50% for the rest of the cohort, n=1399).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
5 material management or governance events in the past 24 months, led by executive changes. Historically, Real Estate names rated neutral grew net income 57% of the time over the next year (vs 55% for the rest of the cohort, n=5004).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.17 → $0.11 (-33.3% / 30d). 0 raised, 2 cut, 2 covering analysts.
0 upgrades, 0 downgrades / 30d, 2 maintained. 81% of analysts rate Buy.
5 PT revisions / 30d. Avg target 15.1% above current price.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$63.
How much price usually moves either way.
On a bad day, this stock has moved -$195.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $1,252.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Valuation label changed from 'expensive' to 'full'.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Earnings affect investor trust and future plans.
Confirms:Net Income per share is above $0.60.
Disproves:Net Income per share is below $0.56.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for VTR yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 15, 2026, Carey S. Roberts, Executive Vice President, General Counsel, Ethics & Compliance Officer and Corporate Secretary of Ventas, Inc. (“Ventas” or the “Company”) notified Ventas of her intention to resign from the Company effective June 26, 2026 (the “Effective Date”). Ms. Roberts intends to join Blackstone, Inc. as Senior Managing Dir…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$93.00 – $110.00 (median $98.00) · 9 analysts · as of 2026-05-22
Looks more expensive than peers.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care REITs.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
VTR Ventas | Typical Show detailsSector percentile: 40 of 100 | full | moderate |
WELL Welltower | Typical Show detailsSector percentile: 58 of 100 | expensive | low |
OHI Omega Healthcare Investors | Typical Show detailsSector percentile: 68 of 100 | expensive | moderate |
DOC Healthpeak Properties | Above typical Show detailsSector percentile: 76 of 100 | fair | moderate |
AHR American Healthcare REIT | Typical Show detailsSector percentile: 41 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-16.
via XLRE
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Ventas aims to increase its 2026 investment volume expectations to $3 billion, focusing on senior housing.
Ventas focuses on driving growth in SHOP Same-Store Cash NOI through operational improvements.
Ventas aims to enhance its financial flexibility and liquidity to support growth initiatives.
Why it matters: Continued growth in SHOP Same-Store Cash NOI shows strong demand for senior housing. It confirms the company's growth strategy.
Confirms:Q2 SHOP Same-Store Cash NOI growth exceeds 15% year-over-year.
Disproves:Q2 SHOP Same-Store Cash NOI growth is below 10% year-over-year.
Why it matters: Changes to FFO guidance show management's view on profits and performance. This can affect investors.
Confirms one read:Management raises FFO per share guidance for 2026 above $3.73.
Confirms the other:Management lowers FFO per share guidance for 2026 below $3.63.
Why it matters: Changes in liquidity can affect Ventas's ability to grow and pay off debt.
Confirms one read:Liquidity goes up to over $6 billion after taking on debt.
Confirms the other:Liquidity drops below $5 billion after taking on debt.
Why it matters: Hitting this target shows strong market momentum and supports long-term growth. It reflects management's confidence in senior housing.
Confirms:Total 2026 senior housing investments reach or exceed $3 billion.
Disproves:Total senior housing investments for 2026 are below $2.5 billion.
Why it matters: Higher interest rates may affect Ventas's money and growth.
Confirms one read:Full year guidance stays stable even with rising interest rates.
Confirms the other:Full year guidance is lowered due to rising interest rates.
Why it matters: Hitting this investment target shows Ventas's commitment to growth in senior housing.
Confirms:$3 billion in senior housing investments will be done by year-end.
Disproves:Investment volume falls short of $2.5 billion by year-end.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 12, 2026, in connection with his previously disclosed retirement on May 1, 2026, Ventas, Inc. (the “Company”) entered into a separation and release agreement with Peter J. Bulgarelli, Executive Vice President, Outpatient Medical & Research, Ventas, Inc. and President and CEO, Lillibridge Healthcare Services, Inc. (the “Separation Agreement”)…
Other Events. On May 15, 2026, the Company entered into Amendment No. 3 (“Amendment No. 3”) to the ATM Sales Agreement, dated September 18, 2024 (the “Original Agreement”), as amended by that Amendment No. 1 to the ATM Sales Agreement, dated June 13, 2025 (“Amendment No. 1”) and by that Amendment No. 2 to the ATM Sales Agreement dated February 9, 2026 (“Amendment No. 2” and together with Amendment No. 1, Amendment No. 3 and the Original Agreement, the “Sales Agreement”), with BofA Securities,…
by reference. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” with the U.S. Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific referenc…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 16, 2026, Gregory R. Liebbe, Senior Vice President, Chief Accounting Officer and Controller informed Ventas, Inc. (the “Company”) that he is resigning to pursue other opportunities. Mr. Liebbe’s last day of employment with the Company will be February 27, 2026. Mr. Liebbe’s decision to resign is not the result of any disagreement with t…